Mapi Hits Milestone For Viatris-Partnered Long-Acting Glatiramer
More Than 600 Patients Now Dosed In Pivotal Phase III Trial
Fresh from a $20m investment from partner Viatris, Mapi Pharma has announced significant progress in its Phase III trial for a long-acting version of Copaxone, which is to be filed through the FDA’s 505(b)(2) hybrid pathway.
You may also be interested in...
Mylan is teaming up with Israeli firm Mapi Pharma to develop and commercialise a long-acting glatiramer acetate product, Mapi’s ‘GA Depot’ candidate. Subject to approval from the Israeli Innovation Authority, the partnership sees Mylan acquire global marketing rights for the once-monthly injection for treating relapsingremitting multiple sclerosis (RRMS).
Coherus BioSciences has sold a little under 2.5 million shares to partner Junshi Biosciences, giving the firm additional capital following a large debt financing last year.
Lotus Pharmaceuticals aims to build a stronghold in Thailand and beyond, after the Alvogen subsidiary announced a partnership with a subsidiary of Thai state-owned conglomerate PTT, which includes a $50m capital injection.